KR102246265B1 - 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도 - Google Patents

5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도 Download PDF

Info

Publication number
KR102246265B1
KR102246265B1 KR1020207007411A KR20207007411A KR102246265B1 KR 102246265 B1 KR102246265 B1 KR 102246265B1 KR 1020207007411 A KR1020207007411 A KR 1020207007411A KR 20207007411 A KR20207007411 A KR 20207007411A KR 102246265 B1 KR102246265 B1 KR 102246265B1
Authority
KR
South Korea
Prior art keywords
compound
cancer
chk1
treatment
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007411A
Other languages
English (en)
Korean (ko)
Other versions
KR20200038990A (ko
Inventor
이안 콜린스
토마스 피터 매튜스
타티아나 파리아 다 폰세카 맥하디
제임스 오스본
마이클 레인치버리
마이클 이안 월턴
미셸 다운 개럿
Original Assignee
캔써 리서치 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캔써 리서치 테크놀로지 리미티드 filed Critical 캔써 리서치 테크놀로지 리미티드
Priority to KR1020217012299A priority Critical patent/KR102341637B1/ko
Publication of KR20200038990A publication Critical patent/KR20200038990A/ko
Application granted granted Critical
Publication of KR102246265B1 publication Critical patent/KR102246265B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207007411A 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도 Active KR102246265B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217012299A KR102341637B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647200P 2012-05-15 2012-05-15
US61/647,200 2012-05-15
PCT/GB2013/051233 WO2013171470A1 (en) 2012-05-15 2013-05-14 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147031572A Division KR102090792B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217012299A Division KR102341637B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도

Publications (2)

Publication Number Publication Date
KR20200038990A KR20200038990A (ko) 2020-04-14
KR102246265B1 true KR102246265B1 (ko) 2021-04-29

Family

ID=48468659

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020207007411A Active KR102246265B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
KR1020247004407A Withdrawn KR20240023685A (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴및 그의 치료적 용도
KR1020227037439A Active KR102635954B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
KR1020147031572A Active KR102090792B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
KR1020217012299A Active KR102341637B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
KR1020217041302A Ceased KR20210156333A (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020247004407A Withdrawn KR20240023685A (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴및 그의 치료적 용도
KR1020227037439A Active KR102635954B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
KR1020147031572A Active KR102090792B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
KR1020217012299A Active KR102341637B1 (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
KR1020217041302A Ceased KR20210156333A (ko) 2012-05-15 2013-05-14 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도

Country Status (19)

Country Link
US (3) US9663503B2 (OSRAM)
EP (2) EP3210980B1 (OSRAM)
JP (2) JP6027230B2 (OSRAM)
KR (6) KR102246265B1 (OSRAM)
CN (2) CN104302635B (OSRAM)
AU (2) AU2013261605B2 (OSRAM)
BR (1) BR112014026801B1 (OSRAM)
CA (1) CA2870837C (OSRAM)
DK (1) DK2855448T3 (OSRAM)
ES (2) ES2624307T3 (OSRAM)
IL (1) IL235133A (OSRAM)
IN (1) IN2014DN09221A (OSRAM)
MX (1) MX358819B (OSRAM)
NZ (1) NZ702050A (OSRAM)
PL (1) PL2855448T3 (OSRAM)
RU (1) RU2659786C2 (OSRAM)
SG (1) SG11201407238VA (OSRAM)
WO (1) WO2013171470A1 (OSRAM)
ZA (1) ZA201408452B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010938A2 (pt) 2011-11-09 2017-05-16 Cancer Res Tech Ltd compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico
PL2855448T3 (pl) 2012-05-15 2017-09-29 Cancer Research Technology Ltd 5-[[4-[[morfolino-2-ilo]metyloamino]-5-(trifluorometylo)-2-pirydylo]amino]pirazyno-2-karbonitryl i jego zastosowanie terapeutyczne
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
ES2768678T3 (es) 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
KR20170016498A (ko) * 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2018094325A1 (en) * 2016-11-18 2018-05-24 The Trustees Of Columbia University In The City Of New York Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer
AU2018243667A1 (en) * 2017-03-31 2019-10-17 Seagen Inc. Combinations of Chk1- and Wee1 - inhibitors
WO2018191299A1 (en) * 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
AU2018250552B2 (en) * 2017-04-10 2022-08-04 Crt Pioneer Fund Lp Chk1 (SRA737)/PARPi combination methods of inhibiting tumor growth
US20200157638A1 (en) * 2017-06-01 2020-05-21 Sierra Oncology, Inc. Biomarkers and patient selection strategies
CN107266897B (zh) * 2017-08-04 2019-05-14 上海跃贝新材料科技股份有限公司 一种低粘度矿物增强pc/pet合金材料及其制备方法
MX2020008881A (es) * 2018-02-26 2021-01-08 Sierra Oncology Inc Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EP3914284A4 (en) * 2019-01-25 2022-10-26 Numedii, Inc. METHODS OF TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
US20220184091A1 (en) * 2019-03-28 2022-06-16 Sierra Oncology, Inc. Methods of Treating Cancer with Chk1 Inhibitors
MX2021013905A (es) * 2019-05-14 2022-05-18 Sierra Oncology Inc Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1.
CN110872277B (zh) * 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途
CN110680928B (zh) * 2019-12-06 2020-04-28 深圳前海港影生物科技有限公司 抑制黑色素合成的偶联物及其在药品和化妆品中的应用
CN110684083B (zh) * 2019-12-06 2020-05-15 北京诺赛启研再生医学研究院有限公司 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用
TW202204348A (zh) * 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
CN117858870A (zh) * 2021-08-17 2024-04-09 葛兰素史密斯克莱知识产权(第3号)有限公司 P2x3拮抗剂的制备
WO2025101691A1 (en) 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044162A1 (en) 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JP4146514B2 (ja) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト ピロロピリミジン類およびその製造方法
US7271261B2 (en) 2001-10-19 2007-09-18 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazoles and imidazo-[4,5]-pyridines
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
EP1442039A1 (en) 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
CA2484209C (en) * 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
US7202244B2 (en) 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
MXPA06001098A (es) 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
CA2542105C (en) 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2542076C (en) 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
CN1882345A (zh) 2003-10-16 2006-12-20 希龙公司 作为raf激酶抑制剂以治疗癌症的2,6－二取代的喹唑啉、喹喔啉、喹啉和异喹啉
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7642354B2 (en) 2004-04-13 2010-01-05 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20090029982A1 (en) 2005-04-28 2009-01-29 Supergen, Inc. Protein kinase inhibitors
WO2007000240A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
JP5405316B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノリン誘導体
ES2485040T3 (es) 2007-03-16 2014-08-12 The Scripps Research Institute Inhibidores de cinasa de adhesión focal
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
GB0803018D0 (en) * 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
BR112014010938A2 (pt) 2011-11-09 2017-05-16 Cancer Res Tech Ltd compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico
PL2855448T3 (pl) 2012-05-15 2017-09-29 Cancer Research Technology Ltd 5-[[4-[[morfolino-2-ilo]metyloamino]-5-(trifluorometylo)-2-pirydylo]amino]pirazyno-2-karbonitryl i jego zastosowanie terapeutyczne

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009044162A1 (en) 2007-10-05 2009-04-09 Cancer Research Technology Limited Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use

Also Published As

Publication number Publication date
AU2017268508A1 (en) 2017-12-14
AU2013261605B2 (en) 2017-08-31
JP2015520753A (ja) 2015-07-23
EP2855448B1 (en) 2017-02-08
US9663503B2 (en) 2017-05-30
JP6027230B2 (ja) 2016-11-16
KR20150023252A (ko) 2015-03-05
DK2855448T3 (en) 2017-05-01
EP3210980A1 (en) 2017-08-30
US20210276990A1 (en) 2021-09-09
PL2855448T3 (pl) 2017-09-29
NZ702050A (en) 2016-08-26
KR102635954B1 (ko) 2024-02-13
BR112014026801B1 (pt) 2022-03-03
ES2981584T3 (es) 2024-10-09
JP6362652B2 (ja) 2018-07-25
SG11201407238VA (en) 2014-12-30
RU2659786C2 (ru) 2018-07-04
KR20240023685A (ko) 2024-02-22
CN104302635B (zh) 2016-07-06
CA2870837A1 (en) 2013-11-21
AU2017268508B2 (en) 2019-07-04
KR20220151007A (ko) 2022-11-11
KR102341637B1 (ko) 2021-12-21
HK1203529A1 (en) 2015-10-30
KR20200038990A (ko) 2020-04-14
RU2014147105A (ru) 2016-07-10
KR20210156333A (ko) 2021-12-24
EP3210980B1 (en) 2024-04-03
US20180022739A1 (en) 2018-01-25
MX358819B (es) 2018-09-05
KR102090792B1 (ko) 2020-03-18
MX2014012881A (es) 2015-04-08
IN2014DN09221A (OSRAM) 2015-07-10
US10259806B2 (en) 2019-04-16
CN104302635A (zh) 2015-01-21
BR112014026801A2 (pt) 2017-06-27
ES2624307T3 (es) 2017-07-13
IL235133A (en) 2017-03-30
WO2013171470A1 (en) 2013-11-21
ZA201408452B (en) 2016-08-31
AU2017268508C1 (en) 2019-10-17
KR20210047981A (ko) 2021-04-30
JP2017036314A (ja) 2017-02-16
US20150126471A1 (en) 2015-05-07
EP2855448A1 (en) 2015-04-08
US11787792B2 (en) 2023-10-17
CN106279142B (zh) 2019-05-03
CA2870837C (en) 2022-05-10
HK1243408A1 (en) 2018-07-13
AU2013261605A1 (en) 2014-11-13
CN106279142A (zh) 2017-01-04

Similar Documents

Publication Publication Date Title
KR102246265B1 (ko) 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
AU2012335409B2 (en) 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
HK1243408B (en) Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200312

Application number text: 1020147031572

Filing date: 20141110

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200407

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200514

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210125

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210423

Application number text: 1020147031572

Filing date: 20141110

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210423

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210426

End annual number: 3

Start annual number: 1

PG1601 Publication of registration